The US FDA has approved icotrokinra, an interleukin-23 (IL-23) receptor antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg who are candidates for systemic therapy or phototherapy. Clinical evidence In a clinical study involving 2500 patients, icotrokinra demonstrated a statistically significant higher proportion of patients achieving clear or almost clear skin compared to both placebo and deucravacitinib.
Dosage and administration Available in tablet form Recommended dosage is 200 mg orally once daily Administer icotrokinra on an empty stomach with water upon waking Wait at least 30 minutes after taking icotrokinra before eating food For patients who have difficulty swallowing tablets, icotrokinra can be dispersed in water Contraindications None Warnings and Precaution…
